U.S. Aerospace & Defense Stock News

Rhythm Pharmaceuticals (RYTM) just received a significant decision from the FDA, as their supplemental New Drug Application for setmelanotide was not only accepted for filing but also granted Priority Review status. This indicates that the agency sees potential for the medication to address an urgent, unmet need for people dealing with acquired hypothalamic obesity. Investors familiar with Rhythm know setmelanotide already has approvals for rare genetic obesity disorders. This proposed...

Thinking about investing in Vulcan Materials, or maybe deciding whether to hold on to your shares? You are in good company. Vulcan Materials has caught the attention of market watchers, especially after its stock price shrugged off some short-term dips and delivered an impressive 16.4% return over the past year. That is a performance hard to ignore, especially when you look at its nearly 143% total return over five years. Recent months have shown a blend of resilience and optimism, with the...

If you have your eye on Live Nation Entertainment stock, you are not alone. With concerts and live experiences roaring back, investors have seen the company’s share price climb an impressive 25% so far this year and over 67% over the past twelve months. That kind of run naturally raises the question: does LYV have more room to run, or is the market already pricing in all that potential? Digging a bit deeper, LYV’s journey has been anything but boring. In just the past three months, the stock...

NasdaqGS:JD 1 Year Share Price vs Fair Value Explore JD.com's Fair Values from the Community and select yours JD.com...

Thinking about what to do with Pony AI stock? You are not alone. As one of the more intriguing names in the autonomous vehicle sector, Pony AI has experienced its fair share of twists and turns recently. For traders and long-term investors alike, the past few months have brought some big price swings that demand a closer look. Let us start with the numbers. After a dip of nearly 28% over the past 90 days, Pony AI has rebounded with a 15.6% climb over the last month. That recent rally, coupled...

Thinking about what to do next with Johnson Controls International stock? You are not alone. Investors have been watching JCI’s distinct price action over the past year and weighing up the company’s future, especially as expectations across the industrial sector keep shifting. After a rollercoaster 2023, the past twelve months have brought a substantial total return of about 53% for Johnson Controls’ shareholders. That impressive run comes in addition to a hefty 104% return over three years,...

Key Insights TROOPS' significant insider ownership suggests inherent interests in company's expansion A total of 3...

If you are trying to make sense of Insulet’s recent run, you are not alone. Whether you already hold shares or are weighing a new buy, it is tough to look away from a stock that has powered up nearly 30% year-to-date and delivered a whopping 79% total return over the past year. The buzz makes sense, with Insulet’s sales up by more than 14% and annual net income growth topping 23%. All of this comes with the shares closing recently at $333, just a modest 5.7% below the average analyst price...

On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider. This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for...

If you have been following Cigna Group (CI) lately, you’ve probably noticed the stock’s share price drifting higher. The increase has been subtle, but just enough to catch the eye. There hasn’t been a single major announcement sparking this move; however, with a share price now sitting above $300 and a year-to-date gain over 10%, many investors are wondering whether the recent momentum is revealing something about sentiment or simply reflects the normal ebb and flow of a maturing company...

W. R. Berkley (WRB) just unveiled Berkley Edge, a brand-new operation dedicated to serving small and mid-sized businesses with professional liability and casualty insurance, especially in cases that are tough to underwrite. This move, along with the appointment of industry veteran Jamie Secor to lead the venture, is a clear statement about where the company sees opportunity: in specialty insurance, targeting risks that many competitors pass by. For investors, this expansion is worth a closer...

If you are sitting on the fence about what to do with BWX Technologies stock right now, you are definitely not alone. With its impressive run over the last year, climbing more than 63%, BWXT has landed squarely on the radar for many investors searching for growth stories and stable plays alike. The stock’s gains are even more eye-catching when you zoom out, doubling over the last three and five years, and surging more than 51% in just the past three months. These outsized returns tell a story...

It is not every day that Novo Nordisk (NYSE:NVO) catches eyes for all the wrong reasons, but this week’s slide has certainly prompted investors to pause. The stock dropped by roughly 0.9% in the past day and now sits a staggering 58% below its level a year ago. While there is no single dramatic event driving these shifts, the persistent decline has many wondering whether this signals deeper issues or simply reflects changing market sentiment around the pharmaceutical sector. Looking at a...

If you have D.R. Horton in your portfolio or have been watching from the sidelines wondering if now is the time to buy, you are not alone. The stock has been anything but boring lately. Over the past month, shares are up roughly 24.5%. Looking back three months, that gain stretches to more than 37%. Even after accounting for a small dip over the last week, the recent surge shows investors are betting on growth, or at least a shift toward renewed optimism around homebuilders. D.R. Horton has...

Suburban Propane Partners reported its third-quarter and nine-month earnings results, showing third-quarter revenue of US$260.15 million and a net loss of US$14.84 million, while nine-month revenue reached US$1.22 billion with net income of US$141.71 million. Despite year-over-year improvements in revenue and net results, concerns remain about the company's high debt, repeated distribution cuts, and use of ATM equity programs. Next, we will examine how these debt and distribution concerns...

NasdaqGS:NVCR 1 Year Share Price vs Fair Value Explore NovoCure's Fair Values from the Community and select yours...

If you have been keeping an eye on Motorola Solutions stock, you know it rarely strays far from investors' radar. Maybe you are wondering if this run can keep going or if it is time to lock in gains. After all, in the last thirty days, MSI's share price has climbed nearly 10%, and over the past year, it has delivered an impressive 9.6% total return. Even more eye-catching is that the stock has more than doubled investors’ money if you stretch the timeline back five years. This is not too...

Thinking about what to do with fuboTV stock? You are not alone. Investors have watched this streaming-focused player deliver some rollercoaster returns lately. Over just the past year, FUBO rocketed up more than 66% in total return. Zoom out, though, and you will see a stock that has lost ground over three and five years. This underscores just how volatile the journey has been. Recently, after some short-term pop, the stock has pulled back a bit, reminding everyone that big price swings are...

NYSE:KEYS 1 Year Share Price vs Fair Value Explore Keysight Technologies's Fair Values from the Community and select...

If you’re wondering what to do with Collegium Pharmaceutical (COLL) in light of their latest earnings report, you’re not alone. The company just posted its second quarter numbers, revealing a drop in earnings compared to last year, but also surprised many by raising its full year revenue guidance. In addition, Collegium provided an update on its aggressive share buyback program, which could speak volumes about management’s confidence or at least their current preferred use of cash. These...

Thinking about what to do with DoorDash stock right now? You are definitely not alone. Whether you have been riding the wave for the past year or are just peeking at the ticker for the first time, there is no denying that DoorDash has been on the move. In the past year, the stock has nearly doubled, delivering a massive 88% total return. The past three months alone have seen a 21% jump, which is remarkable momentum for a company that is already a household name in food delivery. The energy...

Earlier this month, Establishment Labs Holdings raised its 2025 revenue guidance to a range of US$208 million to US$212 million and reported second-quarter sales of US$51.3 million, up from US$44.12 million a year prior. An interesting aspect is the company's forecast of at least US$40 million in US Motiva revenue for the year, marking the growing importance of its US operations in total sales. We'll explore how the stronger full-year revenue outlook and US Motiva momentum could influence...

If you’ve been tracking Brookfield Business (NYSE:BBUC), the recent renewal of its normal course issuer bids for both limited partnership units and class A exchangeable subordinate voting shares probably caught your eye. Management is sending a clear message about their confidence in the firm’s intrinsic value, especially with buyback programs often interpreted as a commitment to shareholder returns. The regulatory filings released alongside this move suggest Brookfield is focused on capital...

NasdaqCM:UBXG 1 Year Share Price vs Fair Value Explore U-BX Technology's Fair Values from the Community and select...